High on Treatment Platelet Reactivity and Stent Thrombosis

Heart Lung and Circulation

Volumn 20, Issue 8, 2011, Pages 525-531

  Rajendran, Saissan ^b   Parikh, Devang ^a   Shugman, Ibrahim ^b   French, John K ^a,b   Juergens, Craig P ^a,b  

^a LIVERPOOL HOSPITAL   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

Antiplatelet; Aspirin; Clopidogrel; Hyporesponsiveness; Stent thrombosis

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; FIBRINOGEN RECEPTOR ANTAGONIST; PURINERGIC P2Y12 RECEPTOR;

ADULT; ANALYTICAL EQUIPMENT; ANGIOGRAPHY; ANTICOAGULANT THERAPY; ARTICLE; BLOOD VESSEL DIAMETER; BLOOD VESSEL REACTIVITY; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DRUG EFFICACY; FEMALE; GROUPS BY AGE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; STENT THROMBOSIS; THROMBOCYTE AGGREGATION INHIBITION;

ADULT; AGED; ANGIOPLASTY; ASPIRIN; CORONARY ARTERY DISEASE; FEMALE; HUMANS; MALE; MIDDLE AGED; PLATELET ACTIVATION; PLATELET AGGREGATION INHIBITORS; STENTS; THROMBOSIS; TICLOPIDINE;

EID: 79960625931     PISSN: 14439506     EISSN: 14442892     Source Type: Journal    
DOI: 10.1016/j.hlc.2011.04.004     Document Type: Article

References (30)

1. James S.K., Stenestrand U., Lindback J., Carlsson J., Schersten F., Nilsson T., et al. Long-term safety and efficacy of drug-eluting versus bare-metal stents in Sweden. N Engl J Med 2009, 360:1933-1945.
2. Ko D.T., Chiu M., Guo H., Austin P.C., Goeree R., Cohen E., et al. Safety and effectiveness of drug-eluting and bare-metal stents for patients with off- and on-label indications. J Am Coll Cardiol 2009, 53:1773-1782.
3. Pfisterer M., Brunner-La Rocca H.P., Buser P.T., Rickenbacher P., Hunziker P., Mueller C., et al. Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents: an observational study of drug-eluting versus bare-metal stents. J Am Coll Cardiol 2006, 48:2584-2591.
4. Iakovou I., Schmidt T., Bonizzoni E., Ge L., Sangiorgi G.M., Stankovic G., et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug eluting stents. JAMA 2005, 293:2126-2130.
5. Kuchulakanti P.K., Chu W.W., Torguson R., Ge L., Sangiorgi G.M., Stankovic G., et al. Correlates and long-term outcomes of angiographically proven stent thrombosis with sirolimus- and paclitaxel-eluting stents. Circulation 2006, 113:1108-1113.
6. Daemen J., Wenaweser P., Tsuchida K., Vaina S., Morger C., Kukreja N., et al. Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study. Lancet 2007, 369:667-678.
7. Smit J.J.J., van't Hof A.W.J., de Boer M.J., Hoorntje J.C.A., Dambrink J.H.E., Gosselink A.T.M., et al. Incidence and predictors of subacute thrombosis in patients undergoing primary angioplasty for an acute myocardial infarction. Thromb Haemost 2006, 96:190-195.
8. Cutlip D.E., Baim D.S., Ho K.K., Popma J.J., Lansky A.J., Cohen D.J., et al. Stent thrombosis in the modern era: a pooled analysis of multicenter coronary stent clinical trials. Circulation 2001, 103:1967-1971.
9. Hall P., Nakamura S., Maiello L., Itoh A., Blengino S., Martini G., et al. A randomized comparison of combined ticlopidine and aspirin therapy versus aspirin therapy alone after successful intravascular-guided stent implantation. Circulation 1996, 93:215-222.
10. Van Werkum J.W., Heestermans A.A., Zomer A.C., Kelder J.C., Suttorp M.J., Rensing B.J., et al. Predictors of coronary stent thrombosis: the Dutch stent thrombosis registry. J Am Coll Cardiol 2009, 53:1399-1409.
11. Waters R.E., Kandzari D.E., Phillips H.R., Crawford L.E., Sketch M.H. Late thrombosis following treatment of in-stent restenosis with drug-eluting stents after discontinuation of antiplatelet therapy. Catheter Cardiovasc Interv 2005, 65:520-524.
12. Ferrari E., Benhamou M., Cerboni P., Marcel B. Coronary syndromes following aspirin withdrawal: a special risk for late stent thrombosis. J Am Coll Cardiol 2005, 45:456-459.
13. King S.B., Smith S.C., Hirshfeld J.W., Jakobs A.K., Morrison D.A., Williams D.O. 2007 focused update of the ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention. J Am Coll Cardiol 2008, 51:172-209.
14. Wang Z.J., Zhou Y.J., Liu Y.Y., Yu M., Shi D.M., Zhao Y.X., et al. Impact of clopidogrel resistance on thrombotic events after percutaneous coronary intervention with drug-eluting stent. Thromb Res 2009, 124:46-51.
15. Gurbel P.A., Bliden K.P., Samara W., Yoho J.A., Hayes K., Fissha M.Z., et al. Clopidogrel effect on platelet reactivity in patients with stent thrombosis: results of the CREST Study. J Am Coll Cardiol 2005, 46:1827-1832.
16. Pinto Slottow T.L., Bonello L., Gavani R., Beauzile P., Sushinsky S.J., Scheinowitz M., et al. Prevalence of aspirin and clopidogrel resistance among patients with and without drug eluting stent thrombosis. Am J Cardiol 2009, 104:525-530.
17. Cutlip D.E., Windecker S., Mehran R., Boam A., Cohen D.J., van Es G.A., et al. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation 2007, 115:2344-2351.
18. VerifyNow® Aspirin Assay Product Insert. San Diego, CA: Accumetrics, revised 9/18/07. Available from: (accessed November, 2009). http://accumetrics.com/products/VerifyNow/docs/VerifyNow_Aspirin_Instructions.pdf.
19. Nielsen H.L., Kristensen S.D., Thygesen S.S., Mortensen J., Pedersen S.B., Grove E.L., et al. Aspirin response evaluated by the VerifyNow aspirin system and light transmission aggregometry. Thromb Res 2008, 123:267-273.
20. Price M.J., Endemann S., Gollapudi R.R., Valencia R., Stinis C.T., Levisay J.P., et al. Prognostic significance of post-clopidogrel platelet reactivity assessed by point-of-care assay on thrombotic events after drug-eluting stent implantation. Eur Heart J 2008, 29:992-1000.
21. de la Torre-Hernandez J.M., Alfonso F., Hernandez F., Elizaga J., Sanmartin M., Pinar E., et al. Drug-eluting stent thrombosis: results from the multicenter Spanish registry ESTROFA (Estudio ESpanol sobre TROmbosis de stents FArmacoactivos). J Am Coll Cardiol 2008, 51:986-990.
22. Moussa I., Di Mario C., Di Francesco L., Reimers B., Blengino S., Colombo A. Subacute stent thrombosis and the anticoagulation controversy: changes in drug therapy, operator technique, and the impact of intravascular ultrasound. Am J Cardiol 1996, 78(suppl 3A):13-17.
23. Cook S., Wenaweser P., Togni M., Billinger M., Morger C., Seiler C., et al. Incomplete stent apposition and very late stent thrombosis after drug-eluting stent implantation. Circulation 2007, 115:2426-2434.
24. Moussa I., Di Mario C., Reimers B., Akiyama T., Tobis J., Colombo A. Subacute stent thrombosis in the era of intravascular ultrasound-guided coronary stenting without anticoagulation: frequency, predictors and clinical outcome. J Am Coll Cardiol 1997, 29:6-12.
25. Gurbel P.A., Bliden K.P., Hiatt B.L., O'Connor C.M. Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation 2003, 107:2908-2913.
26. The C URRENT-OASIS 7 Investigators: dose comparisons of clopidogrel and aspirin in acute coronary syndromes. N Engl J Med 2010;363:930-42.
27. von Beckerath N., Kastrati A., Wieczorek A., Pogatsa-Murray G., Sibbing D., Graf I., et al. A double-blind, randomized study on platelet aggregation in patients treated with a daily dose of 150 or 75mg of clopidogrel for 30 days. Eur Heart J 2007, 28:1814-1819.
28. Wiviott S.D., Braunwald E., McCabe C.H., Horvath I., Keltai M., Hermann J.P.R., et al. Intensive oral antiplatelet therapy for reduction of ischaemic events including stent thrombosis in patients with acute coronary syndromes treated with percutaneous coronary intervention and stenting in the TRITON-TIMI 38 trial: a subanalysis of a randomised trial. Lancet 2008, 371:1353-1363.
29. Wallentin L., Becker R.C., Budaj A., Cannon C.P., Emanuelsson H., Held C., et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009, 361:1045-1057.
30. Patti G., Nusca A., Mangiacapra F., Gatto L., D'Ambrosio A., Di Sciascio G. Point of care measurement of clopidogrel responsiveness predicts clinical outcome in patients undergoing percutaneous coronary intervention. J Am Coll Cardiol 2008, 52:1128-1133.